Literature DB >> 16081515

Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.

Claus Hellerbrand1, Marcus Mühlbauer, Susanne Wallner, Marion Schuierer, Iris Behrmann, Frauke Bataille, Thomas Weiss, Jürgen Schölmerich, Anja-Katrin Bosserhoff.   

Abstract

The methylthioadenosine phosphorylase (MTAP) gene is localized in the chromosomal region 9p21. Here, frequently homozygous deletions occur in several kinds of cancer associated with the loss of tumour suppressor genes as p16 and p15. The aim of this study was to analyse MTAP expression in hepatocellular carcinoma (HCC) and to get an insight into the regulation and functional role of MTAP in hepatocancerogenesis. Compared with primary human hepatocytes MTAP expression was markedly downregulated in three different HCC cell lines as determined by real-time PCR and western blotting. This was not due to genomic losses or mutations but to promoter-hypermethylation. Reduced MTAP-expression was confirmed in vivo in HCC compared with non-cancerous liver tissue on both mRNA and protein levels. To study the functional relevance of the downregulated MTAP expression in HCC, MTAP expression was re-induced in HCC cell lines by stable transfection. In these MTAP re-expressing cell clones the invasive potential was strongly reduced, whereas no effects on cell proliferation were observed in comparison with mock transfected cell clones. Furthermore, in MTAP re-expressing cells interferon (IFN)-alpha and IFN-gamma induced a significantly stronger inhibition of cell proliferation than in mock transfected cells. In conclusion, our results suggest a functional role of MTAP inactivation in HCC development and invasiveness. Furthermore, in the light of a recent report revealing an association between MTAP activity and IFN sensitivity, our findings may have clinical significance for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081515     DOI: 10.1093/carcin/bgi201

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  32 in total

1.  A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.

Authors:  Changzheng Du; Landon J Hansen; Simranjit X Singh; Feiyifan Wang; Ran Sun; Casey J Moure; Kristen Roso; Paula K Greer; Hai Yan; Yiping He
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

2.  Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).

Authors:  Georgi Kirovski; Axel P Stevens; Barbara Czech; Katja Dettmer; Thomas S Weiss; Peter Wild; Arndt Hartmann; Anja K Bosserhoff; Peter J Oefner; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2011-01-28       Impact factor: 4.307

3.  Protective effect of xanthohumol on toxin-induced liver inflammation and fibrosis.

Authors:  Christoph Dorn; Jörg Heilmann; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

4.  Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation.

Authors:  Georgi Kirovski; Erwin Gäbele; Christoph Dorn; Lukas Moleda; Christoph Niessen; Thomas S Weiss; Hella Wobser; Doris Schacherer; Christa Buechler; Hermann E Wasmuth; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2010-08-02

5.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

6.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

7.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

8.  Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

Authors:  Thomas Amann; Frauke Bataille; Thilo Spruss; Katja Dettmer; Peter Wild; Christian Liedtke; Marcus Mühlbauer; Paul Kiefer; Peter J Oefner; Christian Trautwein; Anja-Katrin Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Increased expression of c-Jun in nonalcoholic fatty liver disease.

Authors:  Christoph Dorn; Julia C Engelmann; Michael Saugspier; Andreas Koch; Arndt Hartmann; Martina Müller; Rainer Spang; Anja Bosserhoff; Claus Hellerbrand
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

10.  Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.

Authors:  Mariana Ferreira Leal; Eleonidas Moura Lima; Patrícia Natália Oliveira Silva; Paulo Pimentel Assumpção; Danielle Queiroz Calcagno; Spencer Luiz Marques Payão; Rommel Rodríguez Burbano; Marília Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.